drugset / Trial / NCT07497607
Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, phase II study that is designed to investigate nodal and primary tumor CTV dose de-escalation (30 Gy) in HPV positive oropharyngeal cancer.
Timeline
- Start
- 2026-05-13
- Primary completion
- 2031-05-13
- Completion
- 2036-05-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | Other |
| Background | Cisplatin | Other / unclassified | 100 mg/m2 | Other |